Ondansetron Nasal Delivery: Translating Formulation Properties into Device Performance
2:00 pm - Wednesday 3rd February 2027
- Initial screening of Ondansetron formulations for nasal delivery
- Evaluation of nose-to-brain (N2B) and conventional nasal delivery devices
- Early formulation–device performance insights and key considerations for further development
